Neustar DNS ShieldTM Network Securely Delivers High-speed Web Performance
Neustar, Inc. (NYSE: NSR), a trusted, neutral provider of real-time information services, today announced the public launch of its DNS ShieldTM, a worldwide network of secure private domain name system (DNS) connections between Neustar and its partners. Neustar’s DNS ShieldTM network is independent of public internet networks and embodies an industry-first approach to eliminating latency and security vulnerabilities for DNS traffic within its partner network.
“DNS is the backbone of the Internet, but the original protocol design was slightly flawed and failed to take in to account some of the potential security issues, which now make it an attractive target for attacks,” said Rodney Joffe, SVP and Distinguished Fellow, Neustar. “Optimizing and protecting DNS is a mission-critical task since an outage can result in downtime, network latency, lost revenue, and a negative brand experience.”
The recent emergence of the Mirai botnet, which compromised insecure Internet of Things (IoT) devices, created the perfect environment for massive DDoS attacks on DNS servers, which resulted in major Website outages. The DNS ShieldTM network forms a secure connection between Neustar UltraDNS authoritative servers and the recursive servers of its partners, minimizing the vulnerable points of compromise targeted in distributed denial of service (DDoS) attacks and DNS Spoofing, while lowering the latency of DNS transactions and improving the reliability of query responses significantly.
Neustar’s DNS ShieldTM network supplements a global IP Anycast Network by adding scores of private nodes to the existing 30 public nodes across six continents to answer more than 33 billion queries per day. The Neustar network already includes a purpose-built DDoS mitigation solution that protects its UltraDNS network, but the addition of the DNS ShieldTM network will harden its defenses against attacks by removing traffic entirely from the public Internet domain.
Key benefits and features of the DNS ShieldTM network include:
- Lower Latency – Delivers superior Website performance through its private DNS ShieldTM network, enabling DNS traffic to circumvent general public Internet networking connectivity that is frequently slow and congested, ensuring that even holiday traffic or massively scaling users cannot cause outages or delays. In most cases the DNS ShieldTM network nodes are located within 100 feet of partner recursive servers, reducing network latency to single digit milliseconds – the fastest in the world.
- Enhanced Security – The DNS ShieldTM network creates a private network for DNS resolution within its partner network, eliminating security threats, such as DDoS attacks and cache poisoning attempts by shielding direct DNS connections from public view and excluding public Internet traffic.
- Better Reliability – In the event of a DDoS attack or significant network outage, DNS queries will continue to resolve within the private networks where DNS ShieldTM technology is deployed. This resiliency ensures an optimal network experience for Neustar partners and customers to ensure maximum uptime.
“DNS remains constantly threatened by DDoS attacks, cache poisoning assaults, spoofing attempts, and innocently enough, high volume website traffic, which can all lead to service disruptions for a significant portion of the Internet,” said Joffe. “Neustar is hardwiring the Internet with private network connections between our authoritative servers and our partner’s recursive servers, limiting the potential for our UltraDNS network to succumb to these attacks.”
For more information about the Neustar DNS ShieldTM network, please visit https://hello.neustar.biz/2016-dns-shield-wp-security-lp.html
Every day, the world generates roughly 2.5 quadrillion bits of data. Neustar (NYSE: NSR) isolates certain elements and analyzes, simplifies and edits them to make precise and valuable decisions that drive results. As one of the few companies capable of knowing with certainty who is on the other end of every interaction, we’re trusted by the world’s great brands to make critical decisions some 20 billion times a day. We help marketers send timely and relevant messages to the right people. Because we can authoritatively tell a client exactly who is calling or connecting with them, we make critical real-time responses possible. And the same comprehensive information that enables our clients to direct and manage orders also stops attackers. We know when someone isn’t who they claim to be, which helps stop fraud and denial of service before they’re a problem. Because we’re also an experienced manager of some of the world’s most complex databases, we help clients control their online identity, registering and protecting their domain name, and routing traffic to the correct network address. By linking the most essential information with the people who depend on it, we provide more than 12,000 clients worldwide with decisions—not just data. More information is available at http://www.neustar.biz.
Clinton Karr, 415-590-4611
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program12.12.2017 15:23 | Pressemelding
Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today released its latest Scientific Update for Smoke-Free Products, a regular publication on its research efforts to develop and assess a range of smoke-free alternatives to cigarettes. The latest issue of the Scientific Update can be found at this link. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005891/en/ Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program (Photo: Business Wire) This issue of the Scientific Update provides a closer look at some of the principles and practices on which PMI’s scientific assessment program is built. Director Medical Affairs Dr. Patrick Picavet describes specific examples from PMI’s clinical program that highlight the company’s
Murex to Offer MX.3 Risk, Trading and Post-Trade Solutions on the AWS Cloud12.12.2017 14:00 | Pressemelding
Murex, an industry leader in trading, risk management and processing solutions for capital markets, announced they will run their MX.3 technology platform on Amazon Web Services, Inc. (AWS). With the acceleration of cloud adoption in capital markets, Murex and AWS agreed to collaborate to help clients migrate their Murex application workloads to the AWS Cloud. Murex clients are looking to consolidate more and more of their capital markets activity on the MX.3 platform and this means their need for infrastructure is increasing. New regulatory requirements are also driving financial organizations to use cloud to scale up their computing capacity. Murex is collaborating with AWS to meet the demand from clients to support deployment of the Murex offering on the AWS Cloud. Murex is working on the validation of a range of deployment scenarios, from using AWS Cloud for bursting grid
Darzalex®▼(daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible12.12.2017 13:33 | Pressemelding
Janssen-Cilag International NV (“Janssen”) today announced data from the Phase 3 ALCYONE study, showing Darzalex® (daratumumab) in combination with bortezomib, melphalan and prednisone (VMP) significantly improved clinical outcomes, including reducing the risk of disease progression or death by 50 percent, in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (ASCT).1 These data were accepted as a late-breaking abstract (LBA) for presentation at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, today at 7:30 a.m. ET (Abstract #LBA-4).1 Study findings were simultaneously published in the New England Journal of Medicine (NEJM) . 2 Daratumumab is currently indicated for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for
CTS Engines Announces Senior Management Hire12.12.2017 13:00 | Pressemelding
CTS Engines, the global leader for mature jet engine maintenance, announced today that it had hired Diane E. Cavuoto as Senior Vice President, Supply Chain, in an effort to continue to provide its customers with outstanding engine overhaul services. Ms. Cavuoto will be based in CTS’s Ft. Lauderdale headquarters and will report directly to Vesa Paukkeri, CTS’s President and Chief Operating Officer. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005050/en/ Diane E. Cavuoto, Senior Vice President, Supply Chain, for CTS Engines (Photo: Business Wire) Ms. Cavuoto, most recently Vice President, Strategic Sourcing at Honeywell International, brings years of supply chain management experience to CTS. In her prior role at Honeywell, Ms. Cavuoto managed a global commodity team of 150 employees managing $4
MIPI Alliance Opens Access to its MIPI I3C Sensor Interface Specification12.12.2017 13:00 | Pressemelding
The MIPI® Alliance, an international organization that develops interface specifications for mobile and mobile-influenced industries, today announced it is opening access to its sensor interface specification, MIPI I3C. Starting today, all companies, including those not currently members of MIPI Alliance, may access the MIPI I3C v1.0 specification so they may evaluate the incorporation of the specification into their sensor integration plans and design applications. “MIPI I3C provides a welcome update to the I2C technology that has been widely adopted over the past 35 years. Extending access provides an opportunity to spur innovation and help other industries beyond mobile," said Joel Huloux, chairman of MIPI Alliance. "It helps MIPI members as well, because it supports greater adoption and interoperability, strengthens the ecosystem and provides for a richer
ADC Therapeutics Announces Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-30112.12.2017 11:23 | Pressemelding
ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-301 (camidanlumab tesirine or “Cami-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-301 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Hodgkin’s or non-Hodgkin’s lymphoma Dr. Steven M. Horwitz, Medical Oncologist at Memorial Sloan Kettering Cancer Center in New York City, and Principal Investigator, s
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom